Miami Cancer Institute – Multispecialty Grand Rounds Evaluation - December 12, 2022

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable

	5	4	3	2	1	NA
The skills learned in this CME course enhanced my professional competence.	The skills learned in this CME course enhanced my professional competence. - 5	The skills learned in this CME course enhanced my professional competence. - 4	The skills learned in this CME course enhanced my professional competence. - 3	The skills learned in this CME course enhanced my professional competence. - 2	The skills learned in this CME course enhanced my professional competence. - 1	The skills learned in this CME course enhanced my professional competence. - NA
The skills learned in this CME course will be applied in the treatment of my patients	The skills learned in this CME course will be applied in the treatment of my patients - 5	The skills learned in this CME course will be applied in the treatment of my patients - 4	The skills learned in this CME course will be applied in the treatment of my patients - 3	The skills learned in this CME course will be applied in the treatment of my patients - 2	The skills learned in this CME course will be applied in the treatment of my patients - 1	The skills learned in this CME course will be applied in the treatment of my patients - NA

As a result of attending this conference, to what extent do you agree that you will be better able to: (rate the objectives) *

Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable

	5	4	3	2	1	N/A
Analyze rationales for primary-and metastases-directed therapy (MDT) in managing patients with newly diagnosed/asymptomatic (oligo) metastases.	Analyze rationales for primary-and metastases-directed therapy (MDT) in managing patients with newly diagnosed/asymptomatic (oligo) metastases. - 5	Analyze rationales for primary-and metastases-directed therapy (MDT) in managing patients with newly diagnosed/asymptomatic (oligo) metastases. - 4	Analyze rationales for primary-and metastases-directed therapy (MDT) in managing patients with newly diagnosed/asymptomatic (oligo) metastases. - 3	Analyze rationales for primary-and metastases-directed therapy (MDT) in managing patients with newly diagnosed/asymptomatic (oligo) metastases. - 2	Analyze rationales for primary-and metastases-directed therapy (MDT) in managing patients with newly diagnosed/asymptomatic (oligo) metastases. - 1	Analyze rationales for primary-and metastases-directed therapy (MDT) in managing patients with newly diagnosed/asymptomatic (oligo) metastases. - N/A
Assess evidence on the value of focal therapy in the setting of low-volume metastatic prostate cancer (mPC).	Assess evidence on the value of focal therapy in the setting of low-volume metastatic prostate cancer (mPC). - 5	Assess evidence on the value of focal therapy in the setting of low-volume metastatic prostate cancer (mPC). - 4	Assess evidence on the value of focal therapy in the setting of low-volume metastatic prostate cancer (mPC). - 3	Assess evidence on the value of focal therapy in the setting of low-volume metastatic prostate cancer (mPC). - 2	Assess evidence on the value of focal therapy in the setting of low-volume metastatic prostate cancer (mPC). - 1	Assess evidence on the value of focal therapy in the setting of low-volume metastatic prostate cancer (mPC). - N/A

How satisfied or dissatisfied were you with the following conference content? *

Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied

	5	4	3	2	1
Lecture materials.	Lecture materials. - 5	Lecture materials. - 4	Lecture materials. - 3	Lecture materials. - 2	Lecture materials. - 1
Speaker's effectiveness in addressing the learning objectives.	Speaker's effectiveness in addressing the learning objectives. - 5	Speaker's effectiveness in addressing the learning objectives. - 4	Speaker's effectiveness in addressing the learning objectives. - 3	Speaker's effectiveness in addressing the learning objectives. - 2	Speaker's effectiveness in addressing the learning objectives. - 1

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

What, if any, new skills/strategies will you apply in your clinical practice? *

If you do not plan to implement any new skills/strategies in your clinical practice, what is keeping you from doing so? *

Please provide any additional comments or suggestions.

Name

How did you hear about this course? Other...

You are here

Miami Cancer Institute – Multispecialty Grand Rounds Evaluation - December 12, 2022